Highlights
•Conventional chemotherapies have limited efficacy in treating clear cell renal cell carcinoma (ccRCC) due to its high molecular diversity, low response rates, and prevalent drug resistance.
•Novel compounds were developed to inhibit the expression of BUB1B, a gene identified as a critical factor in ccRCC treatment through transcriptomics analysis.
•These BUB1B-targeting compounds have shown greater efficacy in reducing Caki-1 cell viability compared to conventional treatment options for ccRCC.
Please cite this article as: Y. Bouzian, M. El Hafi, N. Parvizi, W. Kim, M. Subaşioğlu, M. Ozcan, H. Turkez, A. Mardinoglu, Design and evaluation of novel inhibitors for the treatment of clear cell renal cell carcinoma, Bioorganic Chemistry (2024), doi: https://doi.org/10.1016/j.bioorg.2024.10759
